{"id":345165,"date":"2014-06-12T00:00:00","date_gmt":"2014-06-11T22:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/a-new-therapeutic-approach-for-breast-cancer\/"},"modified":"2014-06-12T00:00:00","modified_gmt":"2014-06-11T22:00:00","slug":"a-new-therapeutic-approach-for-breast-cancer","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/a-new-therapeutic-approach-for-breast-cancer\/","title":{"rendered":"A new therapeutic approach for breast cancer"},"content":{"rendered":"

In an initial phase II study in metastatic breast cancer, the HSP90 inhibitor ganetespib has shown promising antitumor activity in HER2-positive and triple-negative breast cancer (TNBC). Due to<\/strong> the favorable side effect profile and the good clinical efficacy already as monotherapy, testing of the substance in combination with taxanes now makes sense.<\/strong><\/p>\n

<\/p>\n

(ka) <\/em>Ganetespib, a compound from a completely new class of drugs, is currently being tested in several tumor entities. Ganetespib is an inhibitor of heat shock protein (HSP) 90, a chaperone to which newly synthesized proteins must bind in order to be activated. “HSP90 drives malignant growth by stimulating various pro-oncogenic proteins,” explained Prof. David A. Cameron, MD, Edinburgh [1]. In luminal subtype breast cancer and TNBC, HSP90 overexpression is associated with an unfavorable prognosis, i.e., increased risk of recurrence, distant metastasis, and mortality.<\/p>\n

Mode of action of Ganetespib<\/h2>\n

Ganetespib blocks the binding of important oncogenic proteins such as HER2, AKT, BRAF or BCR-ABL to HSP90, so that they cannot be converted to the functionally active configuration and are degraded in the proteasome. “It’s a  whole new concept: ganetespib is a targeted therapy, but it inhibits not just a single protein, but multiple molecules important for tumor growth,” Prof. Cameron said. This deactivates driver molecules of oncogenesis, inhibits angiogenesis and metastasis, and enhances the effects of chemotherapy and radiotherapy.<\/p>\n

Is it also safe?<\/h2>\n

Ganetespib has now been evaluated in over 1000 patients and has an acceptable safety profile. The main side effect is usually mild and manageable diarrhea. In NSCLC, second-line therapy with ganetespib plus docetaxel has already been shown to extend progression-free and overall survival compared with docetaxel monotherapy in the GALAXY 1 trial [2].<\/p>\n

The phase II ENCHANT-1 trial is evaluating ganetespib monotherapy in HER2-positive breast cancer, TNBC and luminal subtype breast cancer (Fig. 1) <\/strong>. To date, ten HER2-positive patients and 38 women with TNBC have been enrolled. A clear metabolic response was seen in PET already after short-term therapy: In the HER2-positive tumor, six of seven patients responded, and in TNBC, 18 of 31 evaluable patients responded. Early metabolic response correlated with objective clinical response: complete and partial remissions were achieved in four cases of HER2-positive breast cancer, in two cases of TNBC, and stabilizations were achieved in two and eleven cases, respectively. “Thus, ganetespib has shown a promising signal of antitumor activity in these two tumor types,” Prof. Cameron summarized. He assessed the rapid metabolic response to ganetespib even after short-term therapy as promising.<\/p>\n

<\/p>\n

Continuation of the study<\/h2>\n

The ENCHANT-1 trial is now continuing with recruitment of patients with luminal subtype tumors. In addition, ganetespib is currently being evaluated in the I-SPY-2 program in combination with paclitaxel in locally advanced HER2-negative breast cancer as neoadjuvant therapy.<\/p>\n

Source: European Breast Cancer Conference (EBCC) 9, March 19-21, 2014, Glasgow.<\/em><\/p>\n

Literature:<\/h4>\n
    \n
  1. Cameron D, et al: EBCC 9: Abstr. 190.<\/li>\n
  2. Ramalingam S, et al: ASCO 2013; Abstr #CRA8007.<\/li>\n<\/ol>\n

    InFo Oncology & Hematology 2014; 2(5): 26-27.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    In an initial phase II study in metastatic breast cancer, the HSP90 inhibitor ganetespib has shown promising antitumor activity in HER2-positive and triple-negative breast cancer (TNBC). Due to the favorable…<\/p>\n","protected":false},"author":4,"featured_media":44419,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"HSP90 inhibition","footnotes":""},"category":[11513,11400,11370,11548,11503],"tags":[52648,52656,13646,13554,52665,16452,52661,52670],"powerkit_post_featured":[],"class_list":["post-345165","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-gynecology","category-oncology","category-rx-en","category-studies","tag-act-en-2","tag-bcr-abl-en","tag-braf-en","tag-breast-cancer-en","tag-ganetespib-en","tag-her2-en","tag-hsp90-en","tag-tnbc-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-01 15:17:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":345181,"slug":"une-nouvelle-approche-therapeutique-du-cancer-du-sein","post_title":"Une nouvelle approche th\u00e9rapeutique du cancer du sein","href":"https:\/\/medizinonline.com\/fr\/une-nouvelle-approche-therapeutique-du-cancer-du-sein\/"},"it_IT":{"locale":"it_IT","id":345193,"slug":"un-nuovo-approccio-terapeutico-per-il-cancro-al-seno","post_title":"Un nuovo approccio terapeutico per il cancro al seno","href":"https:\/\/medizinonline.com\/it\/un-nuovo-approccio-terapeutico-per-il-cancro-al-seno\/"},"pt_PT":{"locale":"pt_PT","id":345201,"slug":"uma-nova-abordagem-terapeutica-para-o-cancro-da-mama","post_title":"Uma nova abordagem terap\u00eautica para o cancro da mama","href":"https:\/\/medizinonline.com\/pt-pt\/uma-nova-abordagem-terapeutica-para-o-cancro-da-mama\/"},"es_ES":{"locale":"es_ES","id":345205,"slug":"un-nuevo-enfoque-terapeutico-para-el-cancer-de-mama","post_title":"Un nuevo enfoque terap\u00e9utico para el c\u00e1ncer de mama","href":"https:\/\/medizinonline.com\/es\/un-nuevo-enfoque-terapeutico-para-el-cancer-de-mama\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/345165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=345165"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/345165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/44419"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=345165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=345165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=345165"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=345165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}